Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 19/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21736740 | 0.88 | KLKB1 (0.48) | KLKB1USP2ALDH1A1HPGDTSHR | |
| SCHEMBL21736739 | 0.86 | KLKB1 (0.46) | KLKB1 | |
| SCHEMBL23768852 | 0.78 | KLKB1 (0.45) | KLKB1USP2ALDH1A1HPGDTSHR | |
| SCHEMBL23754165 | 0.77 | KLKB1 (0.47) | KLKB1ALDH1A1HPGDTSHRHIF1A | |
| SCHEMBL29906650 | 0.77 | KLKB1 (0.47) | KLKB1ALDH1A1HPGDTSHRHIF1A | |
| SCHEMBL23769158 | 0.77 | KLKB1 (0.45) | KLKB1ALDH1A1 | |
| SCHEMBL23768889 | 0.77 | KLKB1 (0.45) | KLKB1 | |
| SCHEMBL31357725 | 0.77 | KLKB1 (0.45) | KLKB1ALDH1A1 | |
| SCHEMBL23753986 | 0.77 | KLKB1 (0.45) | KLKB1ALDH1A1 | |
| SCHEMBL23769179 | 0.77 | KLKB1 (0.48) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885USP2 2101/4885ALDH1A1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.